// Post a message

Replying to:

Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in Drug-Resistant Neuroblastoma Preclinical Models.

Zhang L, Wu B, and Baruchel S from the New Agent and Innovative Therapy Program, and Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada have just published in Translational Oncology a preclinical paper entitled : Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models ALK-inhibitor crizotinib is effective in the treatment of ALK-mutated neuroblastoma, but crizotinib (...)

pre-moderation

This forum is moderated beforehand: your contribution will only appear after being validated by a site administrator.

Any message or comment?
  • (To create paragraphs, you simply leave blank lines.)

Who are you? (optional)